Stage 1: GFR >90

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

Observational Study Protocol – Fabry Disease Registry Read More »

Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease

Protocol Name: Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease Read More »

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Indication:  Antineutrophil Cytoplasmic

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Read More »

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)

Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Sponsor: River 3 Renal Indication: Alport Syndrome, Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal) Read More »

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B) Read More »

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim)

Protocol Name: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis Sponsor: Boehringer Ingelheim Indication: FSGS Primary Investigator: Anupkumar Shetty, MD Location: Charlton Office, 2651 Bolton Boone Drive, DeSoto, TX 75115 DETAILS >

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim) Read More »

Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis)

Protocol Name: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease (PERIDOT) Sponsor: Sanofi-Aventis Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis) Read More »